ImmunityBio Stock Quote IBRX - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

9.07

Bid

9.07

Ask

9.12

Volume

14,704,253

8.645 Day's Range 10.01

1.25 52 Week Range 10.53

Market Cap

21.694B

Previous Close

8.97

Open

9.48

Last Trade

9.07

Last Trade Time

Financial Volume

$ 134,844,414

VWAP

9.1704

Average Volume (3m)

7,041,737

Shares Outstanding

667,705,368

Dividend Yield

PE Ratio

-37.20

Earnings Per Share (EPS)

-0.87

Revenue

622k

Net Profit

-583.2M

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cel... ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.immunitybio.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

ImmunityBio Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IBRX. The last closing price for ImmunityBio was $8.97. Over the last year, ImmunityBio shares have traded in a share price range of $ 1.25 to $ 10.53.

ImmunityBio currently has 667,705,368 shares outstanding. The market capitalization of ImmunityBio is $21.69 billion. ImmunityBio has a price to earnings ratio (PE ratio) of -37.20.

Overall Flow

Bullish

Net Premium

572k

Calls / Puts

156.25%

Buys / Sells

131.25%

OTM / ITM

105.00%

Sweeps Ratio

0.02%

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®, ImmunityBio’s recently approved treatment for non-muscle invasive bladder cancer (NMIBC) Serum...

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association

Dr. Sam S. Chang, Professor of Urology at Vanderbilt Cancer Program, to host the program “A Deep Dive with Patrick Soon-Shiong: Next-Generation Immunotherapy for NMBIC” Discussion about the...

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer...

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Designated an FDA Breakthrough Therapy, the novel immunotherapy ANKTIVA activates the body’s natural killer (NK) and killer T-cell immune system to attack tumor cells Therapy stimulates memory T...

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the recent publication of preclinical data in the online issue of Science, First Release indicating that...

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

All participants in the Phase 1 pilot study experienced a marked decrease in the burden of infection, and the procedures were found to be safe and well tolerated N-803 is being studied in three...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	3.96	77.4951076321	5.11	10.53	4.9201	28718698	8.38583272	CS
4	3.45	61.3879003559	5.62	10.53	4.73	11906253	7.19003316	CS
12	4.74	109.468822171	4.33	10.53	3.37	7041737	6.26273156	CS
26	5.37	145.135135135	3.7	10.53	2.665	5578076	5.31122435	CS
52	6	195.439739414	3.07	10.53	1.25	5003412	4.17159275	CS
156	-8.08	-47.1137026239	17.15	18.1399	1.21	2893136	4.7116748	CS
260	-27.48	-75.1846785226	36.55	40.834	1.21	2811736	5.1086456	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BENFBeneficient	$ 6.8001 (254.17%)	31.01M
SGBXSafe and Green Holdings Corporation	$ 5.49 (87.37%)	92.18M
SHOTWSafety Shot Inc	$ 0.45 (45.16%)	644
AIPArteris Inc	$ 8.185 (38.03%)	1.11M
RGFReal Good Food Company Inc	$ 0.85 (37.32%)	4.26M
MNDRMobile health Network Solutions	$ 3.33 (-84.91%)	18.76M
NUVOHoldco Nuvo Group DG Ltd	$ 2.00 (-57.54%)	1.04M
SPTSprout Social Inc	$ 28.82 (-40.15%)	13.47M
UNITUniti Group Inc	$ 4.441 (-26.35%)	21.07M
IPDNProfessional Diversity Network Inc	$ 1.29 (-24.12%)	662.59k
AAPLApple Inc	$ 183.38 (5.98%)	163.22M
SQQQProShares UltraPro Short QQQ	$ 11.08 (-5.94%)	154.59M
JAGXJaguar Health Inc	$ 0.3164 (7.91%)	142.47M
NKLANikola Corporation	$ 0.6526 (6.55%)	106.88M
SGBXSafe and Green Holdings Corporation	$ 5.49 (87.37%)	92.18M